US-based X4 Pharmaceuticals has entered an exclusive agreement with United Arab Emirates (UAE)-based pharmaceutical products wholesaler taiba rare to distribute and commercialise oral Xolremdi ...

X4 Pharmaceuticals announced the validation of its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome, by the European Medicines Agency (EMA). This rare ...

X4 Pharmaceuticals (XFOR) and taiba rare, a taiba Healthcare company with specialty & orphan drug marketing, sales, and distribution ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient ...

The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

In recent transactions disclosed by X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), Chief Commercial Officer Mark Baldry has made significant stock acquisitions amid the company's current $85.6 million market ...

The focus on optimizing the U.S. promotion of XOLREMDI demonstrates the company's commitment to supporting the WHIM syndrome community and enhances potential market growth for the product.

“We look forward to working together to further expand the global reach of Xolremdi for people with WHIM syndrome.” Xolremdi is a selective CXC chemokine receptor 4 (CXCR4) antagonist and ...

The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...